| Factor Information | |
|---|---|
| Data ID | 1843 |
| Factor | 6- minute walking distance |
| Description | The 6- minute walking distance increased significantly after a 2, 4, and 6-month therapy [(488±98.8, 496.3±89.0, and 491.3±114.2 m, respectively; P=0.004, 0.003, and 0.004 vs the distance before medication (317.0 ± 134.1)]. |
| Biomarker | NA |
| Classification | C3 (lifestycle factor - exercise habit) |
| Association | |
|---|---|
| Application | Treatment |
| Objective | 6- minute walking distance increased significantly after a 2, 4, and 6-month therapy |
| p Value | 0.004 |
| Conclusion | Oral bosentan can effectively relieve the symptoms, decrease PA hypertension, and improve exercise tolerance and cardiac function classification in patients with PA hypertension associated with congenital heart disease with good safety and mild side effects. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 554 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/VSD, PDA/AS/PDA/VSD, PDA/DORV, VSD/AVSD/ES |
| Reference | |
|---|---|
| PMID | 25537917 |
| Year | 2015 |
| Title | Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | N/A | |
| Region | Beijing, China | |
| Method | Liver and kidney function, again measured 6MWD, color echocardiography of the heart, and evaluated cardiac function grading, and measured oxygen saturation | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | after 6 month therapy(Treatment) | before medication(Control) |
| Number | 24 | N/A |
| Age | 23.8±17.6 (5~57) years | 23.8±17.6 (5~57) years |
| Gender (Male: Female) | 8:16 | N/A |
| Marker Level | 6- minute walking distance: 491.3±114.2 mm | 6- minute walking distance: 317.0 ± 134.1 m |
